Latanoprost 0.005%: evaluation of its effect on accommodative capacity

Troiano, P.; Oldani, Alessandro; Gozzini, Claudio; Iraci, M.; Dalpozzo, R.; Baratta, Mike; Mattia, M. De

doi:10.1111/j.1600-0420.2000.tb01104.x

Cited by 7 publications

(7 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ciliary muscle also plays a major role in accommodation by altering the anterior curvature of the crystalline lens. Romano and Lograno [13] compared the effects of bimatoprost with the commonly prescribed PGs, latonoprost and travoprost, on human ciliary muscle contraction, and agreed with previous studies [14–19] that PGs might induce pseudomyopia. In contrast, pilocarpine, brimonidine, alpha agonists, and anti-inflammatory agents reduce presbyopia [20–25].…”

Section: Introductionsupporting

confidence: 71%

“…The present study revealed that progression of presbyopia, as indicated by near add power, was accelerated in glaucoma patients with a history of latanoprost eyedrop use compared with healthy subjects with no history of eye disease or eyedrop use. Previous studies [16,19] indicated that latanoprost could reduce accommodation in young subjects after a single instillation and one month of use, and this study is the first study to be conducted in middle- to older aged patients. Although the contractility of the isolated ciliary muscle did not diminish with age, stiffened posterior ciliary muscle attachments might still play a possible role in restricting muscle and lens mobility during accommodation [10].…”

Section: Discussionmentioning

confidence: 79%

“…One of the authors (MA) examined all glaucoma patients and controls, and reviewed medical records to check patient compliance by confirming the frequency and duration of visits, and the amount of prescribed latanoprost. Six months of latanoprost use was a sufficient period since previous studies [16,19] observed participants for 1 and 30 days to confirm significant effects.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Latanoprost could exacerbate the progression of presbyopia

Ayaki¹,

Tsuneyoshi²,

Yuki³

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

PurposeProstaglandin analogues (PG) reduce intra-ocular pressure by enhancing uveoscleral flow at the ciliary body, which controls accommodation via the ciliary muscle. We investigated the effect of PG on accommodation and presbyopia progression in glaucoma patients.MethodsWe conducted a clinic-based, retrospective, cross-sectional study. Inclusion criteria were bilateral phakic patients aged 40–69 years with best corrected visual acuity better than 20/30. Exclusion criteria were any disease affecting vision other than glaucoma and history of ocular surgery. Subjects with no prescription or vision-affecting disease served as controls (n = 260). The glaucoma patients were prescribed eye drops containing 0.005% latanoprost for more than six months (n = 23). We measured the binocular near add power at a distance of 30 cm in both groups and compared the results using Kaplan-Meier analysis.ResultsThe mean age (± SD) of the control subjects was 51.5 ± 5.2 years and 39% were male. Similarly, the glaucoma patients had a mean age of 51.0 ± 7.2 years and 39% were male. There were no significant differences in age, gender, intra-ocular pressure, spherical equivalent, astigmatism, or anisometropia between groups. Survival analysis indicated that the glaucoma patients in this study reached the endpoint (near add power of +3.00 D) significantly earlier than control patients (P = 0.0001; generalized Wilcoxon test).ConclusionsExacerbation of presbyopia progression in glaucoma patients is a potential side effect of latanoprost eyedrops.

show abstract

Section: Introductionsupporting

confidence: 71%

Section: Discussionmentioning

confidence: 79%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Latanoprost could exacerbate the progression of presbyopia

Ayaki¹,

Tsuneyoshi²,

Yuki³

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…In non‐human primates, prostaglandin F2α and latanoprost also have been shown to either have no effect on the ciliary muscle or to result in a mild relaxation of the precontracted ciliary muscle in vitro . Studies on young humans receiving topical latanoprost also demonstrate either no effect or mild reduction in accommodation, suggesting the drug has a neutral effect on the contractility of the ciliary muscle in humans, and pupil changes are minimal (http://www.pfizer.ca/en/our_products/products/monograph/221). These fundamental differences between the effect of topical latanoprost on the iris sphincter and possibly the ciliary muscle in dogs vs. that of humans may explain why there have been no reports, to the author's knowledge, of iridocorneal angle narrowing with topical latanoprost in humans.…”

Section: Discussionmentioning

confidence: 99%

The effect of topical latanoprost on anterior segment anatomic relationships in normal dogs

Tsai

Almazan

Lee

et al. 2012

Veterinary Ophthalmology

View full text Add to dashboard Cite

Objective Topical latanoprost 0.005% is commonly used in dogs with primary angle closure glaucoma (PACG), and marked miosis has been reported in the literature. To further explore the effect of topical latanoprost on anterior segment anatomy, we performed iridocorneal angle biometrics in normal beagle dogs. Methods Thirty-five normal female beagle dogs were assessed using anterior segment optical coherence tomography (AS-OCT). One eye of each dog was scanned with the AS-OCT in the superotemporal quadrant. One drop of latanoprost 0.005% was applied topically, and the OCT scan was repeated 30 min later. Images were imported into ImageJ, and pupil diameter, anterior chamber angle, angle opening distance, angle recess area (ARA), anterior chamber hemifield, and anterior chamber depth were measured. Results A single drop of latanoprost resulted in marked miosis, anterior bowing of the peripheral iris, narrowing of the iridocorneal angle, and shallowing of the anterior chamber. The anterior segment parameters demonstrated a significant reduction (P-value 0.001) from baseline following latanoprost with the exception of the ARA (P = 0.07). Conclusions Latanoprost significantly decreases pupil diameter and narrows the iridocorneal angle in normal female beagle dogs. Therefore, the utility of latanoprost as a prophylactic treatment for PACG in fellow eyes may be limited. Studies using quantitative iridocorneal angle measurements in goniodysgenic dogs are warranted to understand the changes in iridocorneal angle morphology that occur in PACG in response to topical application of latanoprost.

show abstract

“…This clinical finding is supported by many prior investigations in young individuals 25 and animal experiments. 26 It is hypothesized that glaucoma may have a causal effect on presbyopia. In our previous study, near add power was measured as a primary outcome because it is a clinically relevant and useful parameter that can be easily measured in general practice.…”

Section: Introductionmentioning

confidence: 99%

Symptomatic Presbyopia may Develop Earlier in Patients With Glaucoma—A Cross-Sectional Retrospective Cohort Study

Ayaki,

Hanyuda,

Negishi

2024

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose The purpose of this study was to explore risk factors for symptomatic presbyopia, defined as near add power ≥1.50 diopters, in patients with glaucoma. Methods Treated glaucoma (n = 56), untreated glaucoma (n = 21), and control individuals (n = 376), aged 40 to 55 years at first visit, were enrolled in the study, and near add power, retinal thickness, and visual field were examined. The association between near add power and ocular parameters and the odds ratios (ORs) for symptomatic presbyopia were investigated. Survival analysis for symptomatic presbyopia was conducted. Results Age, astigmatic power, mean deviation, and ganglion cell complex thickness were associated with near add power. The OR for symptomatic presbyopia was significant for age (OR = 1.51), astigmatism (OR = 1.01), mean deviation (OR = 0.72), ganglion cell complex thickness (OR = 0.98), treated and untreated glaucoma (OR = 2.09), and use of glaucoma eye drops (OR = 3.33). Survival analysis showed that the treated glaucoma group reached the near add power endpoint of ≥1.50 D (symptomatic presbyopia) significantly earlier than the other two groups, and there was no difference between the control and untreated glaucoma groups. Conclusions Glaucoma patients treated with eye drops may start near correction earlier. Translational Relevance Symptomatic presbyopia may develop earlier in patients with glaucoma, and our findings could further contribute to better management and understanding of presbyopia with glaucoma.

show abstract

Latanoprost 0.005%: evaluation of its effect on accommodative capacity

Cited by 7 publications

References 2 publications

Latanoprost could exacerbate the progression of presbyopia

Latanoprost could exacerbate the progression of presbyopia

The effect of topical latanoprost on anterior segment anatomic relationships in normal dogs

Symptomatic Presbyopia may Develop Earlier in Patients With Glaucoma—A Cross-Sectional Retrospective Cohort Study

Contact Info

Product

Resources

About